{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT01952782",
            "orgStudyIdInfo": {
                "id": "2013P001543"
            },
            "organization": {
                "fullName": "Massachusetts General Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Neuropeptides in Human Reproduction",
            "officialTitle": "Neuropeptides in Human Reproduction",
            "therapeuticArea": [
                "Other"
            ],
            "study": "neuropeptides-in-human-reproduction"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2014-04-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2013-09-24",
            "studyFirstSubmitQcDate": "2013-09-24",
            "studyFirstPostDateStruct": {
                "date": "2013-09-30",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2023-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2023-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Stephanie B. Seminara, MD",
                "investigatorTitle": "Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine",
                "investigatorAffiliation": "Massachusetts General Hospital"
            },
            "leadSponsor": {
                "name": "Massachusetts General Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The investigators are seeking healthy volunteers and volunteers with reproductive disorders for the study of the role of dynorphin in the reproductive system. Dynorphin is a naturally occurring opioid hormone that is blocked by naloxone.\n\nWe hypothesize that naloxone, by blocking dynorphin, will stimulate production of gonadotropin-releasing hormone (GnRH) and kisspeptin, two other naturally occurring reproductive hormones."
        },
        "conditionsModule": {
            "conditions": [
                "Hypogonadotropic Hypogonadism"
            ],
            "keywords": [
                "Reproductive disorders",
                "Hypogonadotropic hypogonadism",
                "Kisspeptin",
                "GnRH",
                "Naloxone"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 128,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Naloxone, Kisspeptin, GnRH",
                    "type": "EXPERIMENTAL",
                    "description": "Intravenous (IV) administration of kisspeptin 112-121, GnRH, and naloxone",
                    "interventionNames": [
                        "Drug: Kisspeptin 112-121",
                        "Drug: Naloxone",
                        "Drug: GnRH"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Kisspeptin 112-121",
                    "description": "Subjects will receive up to 10 IV doses of kisspeptin 112-121",
                    "armGroupLabels": [
                        "Naloxone, Kisspeptin, GnRH"
                    ],
                    "otherNames": [
                        "Metastin 45-54"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Naloxone",
                    "description": "Subjects will receive one IV dose of naloxone followed by an IV infusion of naloxone.",
                    "armGroupLabels": [
                        "Naloxone, Kisspeptin, GnRH"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "GnRH",
                    "description": "Subjects will receive up to 10 doses of IV GnRH",
                    "armGroupLabels": [
                        "Naloxone, Kisspeptin, GnRH"
                    ],
                    "otherNames": [
                        "Gonadotropin-releasing hormone"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Average difference in luteinizing hormone (LH) concentration before and after kisspeptin",
                    "description": "Compares response to kisspeptin on and off naloxone infusion",
                    "timeFrame": "Within 30 minutes of administration"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Ages 21-40 (healthy men and regularly cycling women) OR ages 18-75 (men and women with hypogonadotropic hypogonadism (HH))\n* Normal blood pressure (systolic BP \\<140 mm Hg, diastolic BP \\<90 mm Hg)\n* White blood cell, platelets, prolactin, and thyroid stimulating hormone (TSH)within 90%-110% of laboratory reference range\n* Negative urine drug screen panel\n* Hemoglobin:\n\n  1. For healthy men and healthy regularly cycling women: normal\n  2. For men and women with HH: No less than 0.5 gm/dL below the lower limit of the reference range for normal women\n* Blood urea nitrogen (BUN), creatinine, liver function tests not elevated\n* For healthy subjects: Normal reproductive function and history\n* For healthy subjects: Body Mass Index (BMI) 18.5-30kg/m2\n* For subjects with HH: All medical conditions stable and well controlled\n\nExclusion Criteria:\n\n* History of medication reaction requiring emergency medical attention\n* Illicit drug use\n* Consumption of more than 10 alcoholic drinks per week\n* Difficulty with blood draws\n* Currently seeking fertility, breastfeeding, or pregnant\n* For healthy subjects: history of chronic disease and prescription medication use (with the exception of seasonal allergy medication)\n* For subjects with HH: prescription medications known to affect reproductive endocrine function except for those used to treat the subject's reproductive condition",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Coordinator",
                    "role": "CONTACT",
                    "phone": "617-643-2308",
                    "email": "MGHKisspeptinResearch@partners.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Stephanie B Seminara, MD",
                    "affiliation": "Massachusetts General Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "617-643-2308",
                            "email": "MGHKisspeptinResearch@partners.org"
                        },
                        {
                            "name": "Stephanie B Seminara, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Yee-Ming Chan, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Margaret Lippincott, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "31132118",
                    "type": "DERIVED",
                    "citation": "Lippincott MF, Leon S, Chan YM, Fergani C, Talbi R, Farooqi IS, Jones CM, Arlt W, Stewart SE, Cole TR, Terasawa E, Hall JE, Shaw ND, Navarro VM, Seminara SB. Hypothalamic Reproductive Endocrine Pulse Generator Activity Independent of Neurokinin B and Dynorphin Signaling. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4304-4318. doi: 10.1210/jc.2019-00146."
                },
                {
                    "pmid": "29669934",
                    "type": "DERIVED",
                    "citation": "Chan YM, Lippincott MF, Kusa TO, Seminara SB. Divergent responses to kisspeptin in children with delayed puberty. JCI Insight. 2018 Apr 19;3(8):e99109. doi: 10.1172/jci.insight.99109. eCollection 2018 Apr 19."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007006",
                    "term": "Hypogonadism"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006058",
                    "term": "Gonadal Disorders"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10056",
                    "name": "Hypogonadism",
                    "asFound": "Hypogonadotropic Hypogonadism",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9163",
                    "name": "Gonadal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009270",
                    "term": "Naloxone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000009292",
                    "term": "Narcotic Antagonists"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M12221",
                    "name": "Naloxone",
                    "asFound": "Adapted",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12243",
                    "name": "Narcotic Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                }
            ]
        }
    },
    "hasResults": false
}